Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
0.920
+0.049 (5.57%)
Oct 22, 2024, 4:00 PM EDT - Market closed
Veru Inc. Revenue
Veru Inc. had revenue of $3.95M in the quarter ending June 30, 2024, with 18.34% growth. This brings the company's revenue in the last twelve months to $14.09M, down -6.20% year-over-year. In the fiscal year ending September 30, 2023, Veru Inc. had annual revenue of $16.30M, down -58.59%.
Revenue (ttm)
$14.09M
Revenue Growth
-6.20%
P/S Ratio
7.89
Revenue / Employee
$74,560
Employees
189
Market Cap
134.67M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2023 | 16.30M | -23.06M | -58.59% |
| Sep 30, 2022 | 39.35M | -21.91M | -35.76% |
| Sep 30, 2021 | 61.26M | 18.67M | 43.83% |
| Sep 30, 2020 | 42.59M | 10.79M | 33.92% |
| Sep 30, 2019 | 31.80M | 15.94M | 100.47% |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
| Sep 30, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Quipt Home Medical | 244.23M |
| OptimizeRx | 83.20M |
| Journey Medical | 77.68M |
| 908 Devices | 52.69M |
| Fennec Pharmaceuticals | 48.89M |
| Elutia | 24.99M |
| TriSalus Life Sciences | 24.74M |
| Coya Therapeutics | 9.55M |
VERU News
- 1 day ago - Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss - GlobeNewsWire
- 6 days ago - Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress - GlobeNewsWire
- 5 weeks ago - Veru to Present at the 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Veru Inc. (VERU) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results - GlobeNewsWire
- 2 months ago - Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024 - GlobeNewsWire
- 3 months ago - Veru to Participate in the BTIG Virtual Biotechnology Conference - GlobeNewsWire
- 4 months ago - Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism - GlobeNewsWire